GV20 Oncotherapy (寻百会) was started by expert team from Harvard University. We are devoted in cancer immuno-oncology precision medicine development. GV20 Oncotherapy has created new generation of cancer novel drug discovery and development platform which integrates cancer genomics, antibody drug design and biological big data mining. We are utilizing our technological advantages to search novel immuno-oncology targets, screen tumor-specific fully human antibody and identify robust response biomarkers.